ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. Its product includes Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in 2010 and is based in San Diego, California.